OncoCyte filed to withdraw it’s listing application today. Filed in early October, Biotime investors have waited with anticipation for an update on OncoCyte share distribution and record dates.
Investors shouldn’t be concerned though, the plan has simply changed. With the withdrawal from the OTCBB, a new application was filed for the NYSE. OncoCyte is going to the big boards!
BioTime shares (ISIN: 1136365) will be added to the following TASE Indexes in early trading on Tuesday, October 06, 2015,
- TA 100
Biotime is being added as part of the “fast track” Dual Listing inclusion of new shares on the stock exchange. The next scheduled semi-annual index reconstitution is in December.
The percentage of each stock index will be determined on Wednesday, September 30, 2015.
Source: TASE BTX Events
Big things happening with Biotime and news expected in the near future.
SludgeReports (SR) recommended you buy dips over the last month. SR did, did you?
SludgeReports (SR) has been following the Biotime story for a few years now and recommended it recently as a long term buy and hold.
Recent news items include placement of up to $30 million of stock with institutions and insiders. Neal Bradsher, a Director and large shareholder, scooped up an additional 4 million of those shares.
BioTime, Inc. and Subsidiaries to Raise $31 Million Through Sales of Common Shares
Now Mike Mulroy and Steve Cartt are joining the team! These Questcor veterans add even more credibility to an already phenomenal story unfolding.
Michael H. Mulroy and Stephen L. Cartt Joining BioTime Board of Directors
It would not surprise SR to find out Mulroy and Cartt also took part in the share purchase.
Keep this one on your radar folks! This is a serious team with a lot of experience in the industry and capital markets.
Of note, investors will get the presentation materials before the meetings. Looking forward to more information on this long term hold.
Dr. Wagner will also be meeting with investors in other meetings in New York beginning next week. BioTime plans to file a Form 8-K with the Securities and Exchange Commission next week that will include the OncoCyte presentation materials that will be used in these investor meetings.
On September 15, 2014, our subsidiary OncoCyte Corporation and Abcodia Ltd., a UK-based company focusing on the early detection of cancer, announced their collaboration focused on the development of OncoCyte’s blood-based PanC-Dx™ test for early detection of breast cancer. PanC-Dx™ is a class of non-invasive cancer diagnostics based on OncoCyte’s proprietary set of cancer markers, which were discovered by company scientists through an analysis of broad gene expression patterns in numerous cancer types. OncoCyte is currently sponsoring four clinical studies of PanC-Dx™ in bladder, breast, and lung cancer.
Abcodia has exclusive commercial access to a unique longitudinal biobank of over 5,000,000 serum samples collected through the UK Collaborative Trial for Ovarian Cancer Screening. The biobank was derived from over 200,000 initially healthy volunteers, 50,000 of whom provided samples annually for up to 10 years. Since first recruitment, more than 3,700 individuals have been diagnosed with breast cancer, which generates opportunities to assess serum biomarker changes that occurred years before the diagnosis of breast cancer was made.
The collaboration will begin with an initial study to be completed by the end of 2014. Under the terms of the current agreement, OncoCyte will test the performance of its proprietary PanC-Dx™ cancer markers in detecting breast cancer in a set of patient samples selected from the biobank by Abcodia. If the outcome of this initial study is promising, future studies could proceed and expand into the use of a larger cohort to assess OncoCyte’s PanC-Dx™ cancer markers in a case-controlled longitudinal design. Because of the very large number of samples in the biobank, it may be possible to execute a very large study of PanC-Dx™ much more quickly than otherwise would be possible, potentially accelerating the broad commercialization of the test. The performance of the test in detecting the absence, presence, and development of early breast cancer will be considered in determining the intended use for PanC-Dx™ and the regulatory approval pathway that OncoCyte will pursue. As part of the initial collaboration, OncoCyte retains all rights to develop and market its proprietary breast cancer diagnostic products.
The early detection of cancer and its precursors is associated with improved outcomes for patients. Mammography has been widely used since the 1970s for breast cancer screening in asymptomatic women; in 2010 over 30 million screening mammograms were performed in the US alone. Current US National Cancer Institute (NCI) guidelines recommend screening mammograms every 1 to 2 years in women 40 years and older, while the American Cancer Society and the National Comprehensive Cancer Network both recommend screening mammography every year starting at age 40. This screening in women aged 40 to 74 has been associated with relative reduction in breast cancer mortality of 15% to 20%. However, the NCI estimates that approximately 20% of all breast cancers are not detected by mammography during annual screening which indicates there is an unmet need for a breast-cancer screening test with superior specificity and sensitivity when compared to standard screening mammography. PanC-Dx™ does not involve radiation exposure and could be indicated for all women regardless of age, and could be performed during the course of regular care with a familiar physician at low cost.